SCHEMBL21872141

SCHEMBL21872141

COc1ccc(S(=O)(=O)Cl)c2c1CCCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.52
HSD17B2 P37059 1/20 0.52
RBP1 P09455 1/20 0.50
TRPV4 Q9HBA0 1/20 0.49
ADRA1A P35348 3/20 0.42
ALDH1A1 P00352 5/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.39
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
HTR6 P50406 1/20 0.37
QRFPR Q96P65 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
EPAS1 Q99814 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469794 1.00 HSD11B1 (0.52) HSD11B1HSD17B2RBP1TRPV4ADRA1A
SCHEMBL10969055 0.79 ADRA1A (0.59) HSD11B1HSD17B2RBP1ADRA1AALDH1A1
SCHEMBL4504875 0.75 HTR6 (0.64) TRPV4ADRA1AHTR6QRFPRCA1
SCHEMBL4519109 0.75 HTR6 (0.64) TRPV4ADRA1AHTR6QRFPRCA1
SCHEMBL833885 0.74 ADRA1A (0.59) HSD11B1HSD17B2ADRA1AALDH1A1KDM4E
SCHEMBL2876705 0.73 ALDH1A1 (0.47) ALDH1A1LMNAKDM4EHPGDGAA
SCHEMBL22802458 0.73 HTR2A (0.40) HSD11B1HSD17B2RBP1TRPV4ADRA1A
SCHEMBL12484452 0.73 TSHR (0.33) TRPV4HTT
SCHEMBL1338419 0.73 TRPV4 (0.33) TRPV4ALDH1A1GAAEPAS1HTT
SCHEMBL5848655 0.72 HSD11B1 (0.39) HSD11B1HSD17B2RBP1TRPV4ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US disclosed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 EP disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS PHENEX-FXR GMBH (DE) 2020-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A HSD11B1 2488/4885HSD17B2 2514/4885RBP1 2887/4885
US-20200115357-A1 LIVER X RECEPTORS (LXR) MODULATORS NR1H2, NR1H3, NR1H4 HSD11B1 137/4885HSD17B2 319/4885RBP1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.